All In Biotech

Drug Trial Radar · NCT05077709

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

63

Actual

Start

Apr 11, 2022

Primary completion

Nov 30, 2025

Study completion Feb 8, 2026

Sponsor

Lead sponsor
IO BiotechIndustry
Sponsor type
Industry
Collaborators
Theradex; Almac; NeoGenomics; Merck Sharp & Dohme LLC
First posted
Oct 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)

Conditions

  • Lung Cancer Non Small Cell
  • Head and Neck Squamous Cell Carcinoma
  • Urothelial Carcinoma Bladder

Interventions

  • IO102-IO103 in combination with pembrolizumabDrug

    The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: From date of informed consent until disease progression, death or withdrawal of consent whichever came first, assessed for up to 3 years.

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UC Davis Cancer Center

    Sacramento, California

  • University of California San Diego

    San Diego, California

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • Montefiore Medical Center

    The Bronx, New York

  • University of Toledo Medical Center

    Toledo, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology)

    Barcelona, Spain

  • Hospital Universitari de Girona Doctor Josep Trueta

    Girona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Sevilla, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Valencia, Spain

  • Hospital Clínico Lozano Blesa

    Zaragoza, Zaragoza, Spain

  • Velindre Cancer Center

    Cardiff, United Kingdom

  • Guys and St Thomas Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.